Thalidomide for the treatment of leptomeningeal multiple myeloma.
Yutaka
Hattori
H
Mariko
Yabe
Y
Shinichiro
Okamoto
O
Kunihiko
Morita
M
Yusuke
Tanigawara
T
Yasuo
Ikeda
I
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D008558:Melphalan / Q000008:administration & dosage; D008577:Meningeal Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D009607:Nitrosourea Compounds / Q000008:administration & dosage; D011239:Prednisolone / Q000008:administration & dosage; D011241:Prednisone / Q000008:administration & dosage; D013792:Thalidomide / Q000008:administration & dosage*; D014751:Vindesine / Q000008:administration & dosage
D020533:Angiogenesis Inhibitors; D007074:Immunoglobulin G; D009607:Nitrosourea Compounds; D013792:Thalidomide; D005047:Etoposide; D004317:Doxorubicin; D011239:Prednisolone; D008558:Melphalan; D014751:Vindesine; D011241:Prednisone